FLT3 Protein, Human, Recombinant (T227M, His)

Catalog No. TMPY-01247 Copy Product Info

FLT3 Protein, Human, Recombinant (T227M, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 59.7 kDa and the accession number is P36888-1.

FLT3 Protein, Human, Recombinant (T227M, His)

Catalog No. TMPY-01247

Copy Product Info

FLT3 Protein, Human, Recombinant (T227M, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 59.7 kDa and the accession number is P36888-1.

Pack Size	Price	USA Stock	Global Stock
5 μg	$55	-	In Stock
10 μg	$86	-	In Stock
20 μg	$139	-	In Stock
50 μg	$269	-	In Stock
100 μg	$451	-	In Stock
200 μg	$798	7-10 days	7-10 days
500 μg	$1,690	7-10 days	7-10 days

Add to Cart

Add to Quotation

For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Resource Download

COA User Guide of Recombinant Proteins

Product Information

Biological Activity	Measured by its ability to bind biotinylated human FLT3L-His in a functional ELISA.
Description	FLT3 Protein, Human, Recombinant (T227M, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 59.7 kDa and the accession number is P36888-1.
Species	Human
Expression System	HEK293 Cells
Tag	C-His
Accession Number	P36888-1
Synonyms	STK1,fms-related tyrosine kinase 3,FLK-2,FLK2,CD135
Construction	A DNA sequence encoding the extracellular domain of human FLT3 (P36888-1, with natural variant Thr 227 Met) (Met1-Asn541) was expressed with a C-terminal polyhistidine tag. Predicted N terminal: Asn 27
Protein Purity	> 95 % as determined by SDS-PAGE
Molecular Weight	59.7 kDa (predicted); 85-95 kDa (reducing condition, due to glycosylation)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	The cluster of differentiation (CD) system is commonly used as cell markers in Immunophenotyping. Different kinds of cells in the immune system can be identified through the surface CD molecules which associating with the immune function of the cell. There are more than 320 CD unique clusters and subclusters have been identified. Some of the CD molecules serve as receptors or ligands important to the cell through initiating a signal cascade which then alter the behavior of the cell. Some CD proteins do not take part in cell signal process but have other functions such as cell adhesion. CD135, also known as FLT-3, FLK-2, is a member of the CD system. CD135 is an important cell surface marker recognized by specific sets of antibodies to identify the types of hematopoietic (blood) progenitors in the bone marrow and it function to differentiate hematopoietic stem cells, which are CD135 negative, from multipotent progenitors, which are CD135 positive. CD135 is a receptor tyrosine kinase typeⅢ for the cytokine Flt3 ligand and activat signaling through second messengers by binding to Flt3. Signaling through CD135 is important for lymphocyte development. The encoding gene CD135 is a proto-oncogene to which mutations happened will lead to cancer such as leukemia.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy